HealthSignals coverage organized by therapeutic area: oncology, cardio-metabolic disease, rare and genetic diseases, neuroscience, immunology and infectious diseases across Latin America and the United States.
Chileans spend nearly US$100 million a year on weight-loss treatment, according to La Tercera, as seven generic semaglutide applications — including Laboratorio Chile’s Selfix — await regulatory review, putting Novo …
Telix Pharmaceuticals agrees to acquire ITM Isotope Technologies Munich for up to $2.35 billion, securing isotope supply and adding ITM-11, a Phase 3 neuroendocrine tumour candidate that received an FDA …
Cristália’s Phase 1 safety trial of polilaminina for acute spinal cord trauma was scheduled to begin 24 September 2026 after authorisation from Brazil’s health regulator, Anvisa, in January — with …
The FDA approved belzutifan plus lenvatinib for adults with advanced clear cell renal cell carcinoma after prior immunotherapy, adding a second approved indication for belzutifan in 2026 and expanding Merck …
The FDA has approved insulin efsitora alfa-gobe (Onswik), Eli Lilly’s once-weekly basal insulin for adults with type 2 diabetes, making it the second such agent cleared in the US and …
The FDA has approved zilurgisertib (Atebrioz) for fibrodysplasia ossificans progressiva in patients aged 12 and older, making it the third approved FOP therapy and the second in five weeks.
Biolab, a Brazilian pharmaceutical company, has been selected by the UN-backed Medicines Patent Pool to manufacture and sell baloxavir marboxil (Xofluza), Roche’s single-dose oral influenza treatment, in Brazil under a …
The FDA has approved a label update for sotatercept (Winrevair) incorporating HYPERION trial data, extending the drug’s clinical evidence base to recently diagnosed pulmonary arterial hypertension patients on background therapy.
Mercado Livre launched prescription medicine sales in São Paulo on 25 September 2026, including GLP-1 drugs and antibiotics, as pharmacy chain shares fell sharply and Abrafarma said it would formally …
The European Commission has approved obicetrapib, as Ubeslo and as Evlarco (with ezetimibe), for adults with primary hypercholesterolaemia or mixed dyslipidaemia — what the companies call a first-in-class approval for …
You must be logged in to post a comment.